Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more

451 D Street, Boston, MA, 02210, United States

Biotechnology
Healthcare

Market Cap

220.4M

52 Wk Range

$4.70 - $14.93

Previous Close

$12.18

Open

$12.18

Volume

51,357

Day Range

$11.96 - $12.39

Enterprise Value

216.5M

Cash

18.56M

Avg Qtr Burn

-6.797M

Insider Ownership

30.88%

Institutional Own.

13.93%

Qtr Updated

12/31/25